Rajaonera, David
Bejarano-Quisoboni, Daniel
Grill, Jacques
Allodji, Rodrigue S.
Pelletier-Fleury, Nathalie
Journy, Neige
Boussac, Marjorie
Doz, François
Vu-Bezin, Giao
Zidane, Monia
Schwartz, Boris
Haddy, Nadia
Bolle, Stéphanie
El-Fayech, Chiraz
Dufour, Christelle
Diallo, Ibrahima
Schleiermacher, Gudrun
Fresneau, Brice
de Vathaire, Florent
Funding for this research was provided by:
The French Society of Cancer in Children and Adolescents
The Gustave Roussy Foundation
Institut National Du Cancer (INCA RISP-SHS 2022)
Article History
Received: 5 December 2023
Accepted: 9 August 2024
First Online: 10 September 2024
Declarations
:
: In accordance with French regulations, the study protocol was approved by a regional ethics committee of the INSERM and by the French Data Protection Authority (<i>Commission Nationale de l’Informatique et des Libertés – CNIL</i> Authorization n°902287<i>).</i> Individual patient informed consent was not required for this study because we obtained a specific act in law from the French “Conseil d’Etat”, the highest court in France (Order 2014-96 of 2014 February 3), that approved access to the SNDS for all survivors included in the FCCSS.
: Not applicable.
: The authors declare no competing interests.